Metropolis Healthcare reported robust Q4 FY2026 results, achieving a standalone net profit of INR 43.24 crore. The Board of Directors declared a 2nd interim dividend of INR 1/- per share for FY2025-26, with the record date set for May 19, 2026. Additionally, the company announced the appointment of Deloitte Haskins & Sells Chartered Accountants LLP as the new statutory auditor for a five-year term beginning at the upcoming 26th Annual General Meeting.
Financial Highlights for FY2026
For the quarter ended March 31, 2026, Metropolis Healthcare recorded standalone revenue from operations of INR 352.03 crore, reflecting significant growth compared to the previous year. The annual standalone performance for FY2026 showcased a strong profit after tax of INR 157.48 crore, demonstrating operational resilience. On a consolidated basis, the company reported an even stronger annual profit after tax of INR 191.18 crore, underscoring the expansion of its subsidiary network.
Strategic Dividend Payout
In a move to reward shareholders, the Board has declared a 2nd interim dividend of INR 1/- per equity share, based on a face value of INR 2/-. Investors should note that the record date for the eligibility of this dividend is May 19, 2026, with the payment scheduled to be processed within 30 days of the declaration.
Auditor Transition and Leadership Update
As part of its standard governance process, the company will transition to new statutory auditors. Deloitte Haskins & Sells Chartered Accountants LLP has been recommended to replace the retiring B S R & Co. LLP. This appointment is subject to shareholder approval at the upcoming 26th Annual General Meeting and will cover a five-year term extending through the conclusion of the 31st Annual General Meeting.
Additionally, the company announced a shift in its senior leadership. Dr. Nilesh Shah will transition from his full-time role as President – Internal Assurance to an advisory capacity, effective May 14, 2026.
Source: BSE
